Cardiopulmonary bypass equipment operates the heart and lungs and in turn circulates oxygenated blood throughout the body. It also maintain perfusion to other body tissues and organs while the surgeon works in a bloodless surgical field. The machine may consist of venous and arterial cannula (tubes), polyvinyl chloride (PVC) or silicone tubing, reservoir (to hold blood), bubbler or membrane oxygenator, cardiotomy (filtered reservoir), heat exchanger(s), arterial line filter, pump(s), flow meter, inline blood gas and electrolyte analyzer, and pressure-monitoring devices.
The global cardiopulmonary bypass equipment market is estimated to be valued at US$ 118.0 million in 2022 and is expected to exhibit a CAGR of 1.7% during the forecast period (2022-2030).
Figure 1. Global Cardiopulmonary Bypass Equipment Market Share (%), by Product Type, 2022
To learn more about this report, request a free sample copy
Increasing number of cardiovascular disease is expected to drive growth of the cardiopulmonary bypass equipment market
The increase in the prevalence of cardiovascular diseases like atrial fibrillation, atrial flutter and supraventricular tachycardia, decrease in heart muscle elasticity, decrease in heart output, aging population are the driving factors for the growth of cardiopulmonary bypass equipment market. For instance, in June 2020, according to the data published by the American Heart Association, in the U.S. alone, at least 3 to 6 million people have atrial fibrillation, and the numbers are projected to reach approx6 to 16 million by 2050. In Europe, prevalent atrial fibrillation in 2017 was approx12 million among individuals older than 55 years and is expected to reach 14 million by 2060. It was estimated that by 2050 atrial fibrillation (AF) will be diagnosed at least in 72 million individuals in Asia, approx3 million with AF-related strokes.
Figure 2.Global Cardiopulmonary Bypass Equipment Market Share (%), by Region, 2022
To learn more about this report, request a free sample copy
Increasing number of organ transplant surgeries is expected to drive growth of the market over the forecast period.
Increasing number of organ transplant surgeries is expected to drive growth of the market over the forecast period. For instance, according to Organ and Tissue Authority of Australian Government, the number of surgeries performed for organ transplant in 2017 were around 1, 469. Moreover, around 1,400 Australians are waiting for organ transplant. Moreover, in October 2021, according to the data published by Australian Government Organ and Tissue Authority there were currently around 1,750 Australians on the waitlist for an organ transplant. There are also more than 13,000 additional people on dialysis, where some may need a kidney transplant. Australian Government Organ and Tissue Authority gave the exact number of heart transplantation surgery performed in the Australia which was 112 hearts transplantation surgeries were performed in 2021.
Cardiopulmonary Bypass Equipment Market Report Coverage
|Market Size in 2022:
|US$ 118.0 Mn
|Historical Data for:
|2017 to 2020
|2022 to 2030
|Forecast Period 2022 to 2030 CAGR:
|2030 Value Projection:
|US$ 135.1 Mn
Medtronic Plc, LivaNova PLC, MAQUET Holding B.V. & Co. KG., Terumo Corporation, Braile Biomedica, and Tianjin Medical
|Restraints & Challenges:
Global Cardiopulmonary Bypass Equipment Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a negative impact on the global cardiopulmonary bypass equipment market, owing to the decreasing in the number of surgeries performed due to high risk of corona virus. For instance, in February 2022, according to the data published by the National Center for Biotechnology Information, the COVID-19 pandemic caused a dramatic decrease in surgical volume and outpatient medical follow-up. Surgery and SARS-CoV-2 are interlinked. Surgery makes a patient susceptible to COVID-19 infection since, for one, it increases the risk of exposure to the infection in the hospital. Additionally, the chance of developing more severe complications of COVID-19 is relatively high due to the associated immunosuppressive response to surgery and the inflammatory cytokine storm associated with COVID-19 infection and hence number of chronic surgeries performed was lowered down.
Global Cardiopulmonary Bypass Equipment Market: Key Developments
In May 2022, Koninklijke Philips N.V., health Technology Company, demonstrates technology leadership in Magnetic resonance imaging for advanced diagnostics and demanding clinical research programs at International Society for Magnetic Resonance in Medicine annual meeting 2022. Philips unveils AI enabled patient-centric MR portfolio at this year’s International Society for Magnetic Resonance in Medicine annual meeting. Magnetic Resonance Workspace, which also leverages AI technology, simplifies the path from image acquisition to diagnosis, helping to improve MR workflows, enhance the staff experience, and drive productivity and predictability.
Global Cardiopulmonary Bypass Equipment Market: Restraint
The major factors that hinder growth of the global cardiopulmonary bypass equipment market include recall of the components of cardiopulmonary bypass equipment. For instance, on June 08 2022, The U.S. Food and Drug Administration recalled by Medtronic’s Heart Ware Ventricular Assist Device (HVAD) Pump Implant Kit. The FDA has indicated that this is a Class I recall, where continued use of the device may cause serious injury or death. Medtronic is recalling the HVAD Pump Implant Kit because of a pump weld defect, which has led to cases where moisture is able to enter the pump and cause the internal magnets in the device to corrode and demagnetize.
Major players operating in the global cardiopulmonary bypass equipment market include Medtronic Plc, LivaNova PLC, MAQUET Holding B.V. & Co. KG., Terumo Corporation, Braile Biomedica, and Tianjin Medical
Frequently Asked Questions